Contact

+33 01 82 73 24 63

  • En
Pharmablue
  • Early Access Programs
    • About Early Access in France
    • Our Early Access Services
  • Exploitant Status
    • About Exploitant status
    • Our Exploitant Services
  • About us
    • About us
    • Our commitments
      • Quality Policy
      • Data Privacy Policy
  • Ressources
  • Glossary
  • Contact us
    • Send us a message
    • Office locator
  • Early Access Programs
    • About Early Access in France
    • Our Early Access Services
  • Exploitant Status
    • About Exploitant status
    • Our Exploitant Services
  • About us
    • About us
    • Our commitments
      • Quality Policy
      • Data Privacy Policy
  • Ressources
  • Glossary
  • Contact us
    • Send us a message
    • Office locator
Pharmablue / Early Access to market

Categories

  • All All
  • Blog Posts Blog Posts
  • Papers Papers
  • Webinars Webinars
Blog Posts

Blog Posts

 - 

6 March 2025

Benefits of using a third party Exploitant to run early access programs in France and more

Main benefits of outsourcing "Exploitant" status : Reminder : French regulatory authorities require having an « Exploitant » authorized and established in France to manage an early access program in France or a Marketing authorization.  Immediate activation of French Affiliate…

Papers

Papers

 - 

6 March 2025

5 must-knows for US biotechs looking to run Early Access Programs in France

Download the 5 must-know for US Biotechs looking to run Early Access Programs in France: Regulatory Constraints - The Exploitant Financial and Resources Constraints Administrative and Management Constraints New Regulations in 2021 French fast evolving regulations

Papers

Papers

 - 

6 March 2025

French Early Access Program management for a US pharmaceutical company

An American pharmaceutical company starting to build its European affiliates entrusted PharmaBlue with the responsibility of submitting, obtaining, and implementing a French Early Access Program for its orphan drug. PharmaBlue support them for the whole process of submission (advice, writing…

Papers

Papers

 - 

6 March 2025

5 common mistakes companies face when navigating French Early Access Programs

Download the 5 common mistakes companies face when navigating French Early Access Programs: Planning from the early stage Not enough European/French resources available Partner with a "low-cost" Exploitant Early Access Programs - Differences in Regulation and Implementation Changing regulations that…

Papers

Papers

 - 

6 March 2025

Drugs Eligibility criteria for early access programs in France

You are not familiar with the fast evolving Early Access French regulation and Exploitant Status ? Download the list of requirements for the Early Access program.

Aller à la page précédente Aller à la page 1 Aller à la page 2 Aller à la page 3 Aller à la page suivante

Contact our experts today

Composed of proven experts from the pharmaceutical industry, our team is ready to answer your needs and support you to bring your innovative therapies to patients with unmet medical needs

Send a request

About us

Welcome to PharmaBlue a PharmaLex company. PharmaBlue is a partner “Exploitant” of innovative Pharma Companies for the marketing in France of their medicinal products which have been granted an Early access authorization (EAP previously ATU) or a Marketing Authorization (MA)

 

PharmaBlue holds an “Etablissement Pharmaceutique Exploitant” license from ANSM and can take over the organisation and supervision of the distribution in France of pharmaceuticals products.

Links

  • News & Resources
  • Terms of use
  • Data Privacy Policy
  • Patient information notice
  • Healthcare Profesionals information notice

Get in touch

  • +33 01 82 73 24 63
  • Pharmablue